文献速递淋巴瘤

Fcγ受体单核苷酸多态性不影响淋巴瘤患者奥妥珠单抗/利妥昔单抗疗效

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

研究基于GALLIUM和GOYA试验,对初治晚期滤泡性淋巴瘤(FL)和弥漫大B细胞淋巴瘤(DLBCL)患者进行FCGR2A、FCGR3A、FCGR2B基因分型,评估其与无进展生存期(PFS)的关系。结果显示FcγR基因型与利妥昔单抗/奥妥珠单抗联合化疗的疗效无关。

要点

  • FCGR2A和FCGR3A多态性在FL和DLBCL中均无预后影响。
  • FCGR2B I232T与FL中奥妥珠单抗组PFS相关,但多重检验校正后无统计学意义。
  • FCGR2B T232T与DLBCL利妥昔单抗组较差PFS相关,但该基因型罕见(n=13)。

核心结论

  • FcγR基因型与初治晚期FL或DLBCL患者对利妥昔单抗/奥妥珠单抗联合化疗的反应无关。

研究设计与样本

  • 研究基于GALLIUM(n=1202)和GOYA(n=1418)两项临床试验,提取患者基因组DNA,对FCGR2A R131H(rs1801274)、FCGR3A F158V(rs396991)和FCGR2B I232T(rs1050501)进行基因分型,分析其与研究者评估的PFS的关系。

临床怎么用

  • FcγR基因分型不应常规用于指导初治晚期FL或DLBCL患者的利妥昔单抗/奥妥珠单抗治疗选择。

局限性

  • FCGR2B T232T基因型在DLBCL中罕见(n=13),相关发现需谨慎解读。
  • 多重检验校正后多数关联失去统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Single-nucleotide polymorphisms (SNPs) have been shown to influence Fcγ receptor (FcγR) affinity and activity, but their effect on treatment response is unclear. We assessed their importance in the efficacy of obinutuzumab or rituximab combined with chemotherapy in untreated advanced follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the GALLIUM (www.clinicaltrials.gov #NCT01332968) and GOYA (#NCT01287741) trials, respectively. Genomic DNA was extracted from patients enrolled in GALLIUM (n = 1202) and GOYA (n = 1418). Key germline SNPs, FCGR2A R131H (rs1801274), FCGR3A F158V (rs396991), and FCGR2B I232T (rs1050501), were genotyped and assessed for their impact on investigator-assessed progression-free survival (PFS). In both cohorts there was no prognostic effect of FCGR2A or FCGR3A. In FL, FCGR2B was associated with favorable PFS in univariate and multivariate analyses comparing I232T with I232I, with a more modest association for rituximab-treated (univariate: hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.54-1.14; P = .21) vs obinutuzumab-treated patients (HR, 0.56; 95% CI, 0.34-0.91; P = .02). Comparing T232T with I232I, an association was found for obinutuzumab (univariate: HR, 2.76; 95% CI, 1.02-7.5; P = .0459). Neither observation retained significance after multiple-test adjustment. FCGR2B was associated with poorer PFS in multivariate analyses comparing T232T with I232I in rituximab- but not obinutuzumab-treated patients with DLBCL (HR, 4.40; 95% CI, 1.71-11.32; P = .002; multiple-test-adjusted P = .03); however, this genotype was rare (n = 13). This study shows that FcγR genotype is not associated with response to rituximab/obinutuzumab plus chemotherapy in treatment-naive patients with advanced FL or DLBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Strefford JC, Nowicka M, Hargreaves CE, et al. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood Adv. 2021. PMID: 34323957. doi:10.1182/bloodadvances.2020003985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。